VINS Bioproducts Limited entered the arena of biologicals and bio-pharmaceuticals at the turn of the century with a view to produce life saving drugs for rural areas. Early on, the company focused on finding remedies for diseases that are endemic in India, the tropics and other less developed nations. True to its initial objective, the company commenced work to develop AntiSnake Venom Serum (ASVS), which was launched in early 2000. VINS' ASVS, is a life saving product much needed in rural areas where people engaged in agriculture activities are regularly exposed to snake bites. VINS’ ASVS is available in the ready to inject liquid form and the lyophilized form, which is easy to handle, transport and store. The product was well accepted and enjoys today, a market share of almost 40% of the Indian ASVS market.Spurred on by the initial success, the company took up the development of Anti Rabies Serum (ARS). World Health Organization (W.H.O.) estimates that 75% of deaths caused by rabies world-wide, occur in India, Bangladesh and Pakistan alone. W.H.O. recommends Anti Rabies Serum (ARS) along with anti rabies vaccine (ARV) to be injected in all Category III and immuno-compromised Category II rabies cases. Severe shortage of the serum / exorbitant costs of the serum imported from Europe hampered the application of the regimen especially in the developing world.VISION:VINS brings to the world - life saving, bio-pharmaceutical and biological products, and deliver value to customers and stakeholders.MISSION* State-of-the-art manufacturing capabilities.* Internationally benchmarked quality and regulatory systems.* Human resource development through training, monitoring, Leadership and empowering.* Customer relationships through outstanding products and services.* Research and business partnership management.* Strong and visible support for the quality system ensures its implementation throughout the organization.* Quality should be built into the product because testing alone cannot be relied on to ensure product quality.
